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Activity of HMR3004 against Mlrcobacterium avium 
complex in vitro, in human macrophages and in beige 
mice 
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'Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research 
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Objective: To evaluate in vitro, in a cultured macrophage system and in beige mice, the potential therapeutic activity 
of HMR3004, a new ketolide, against organisms of the Mycobacterium avium complex (MAC). 
Methods: The activity of HMR 3004 against MAC was evaluated in vitro (BACTEC) method) in the human macrophage 
system and in the beige mouse model. 
Results: HMR3004 was inhibitory for 50% of 24 MAC strains at 8 mg/L and for 90% of the MAC strains at 16 mg/L by 
the radiometric macrobroth dilution method. The activity in vitro was improved if the MIC determination was carried 
out at pH 7.2 instead of pH 6.8. When tested in the macrophage system against three strains of MAC, HMR3004 showed 
inhibitory activity when used at  0.25 mg/L compared with untreated controls. Administration of HMR3004 to beige mice 
infected with MAC 101 strain caused significant reduction in the number of bacteria in the blood, liver and spleen. The 
reductions were dose-related, with 200 mg/kg per day for 4 weeks being more effective than 100 mg/kg per day or 
50 mg/kg per day (although a dose-dependent relationship was not observed in mortality). 
Conclusion: The ketolide HMR3004 has been shown to be active against MAC, and further assessment of both the 
therapeutic and prophylactic activity are warranted. 
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INTRODUCTION 
Infection with organisms of the Mycobacterium avium 
complex (MAC) occur in approximately 40-50% of 
patients with acquired immunodeficiency syndrome 
(AIDS) with less than 50 CD4+ T-lymphocytes/mm3 
of blood [1,2]. Macrolides such as azithromycin, 
clarithromycin and roxithromycin, as well as agents 
such as rifabutin and ethambutol, have demonstrated 
activity against MAC in vitro, in experimental animal 
models and in clinical trials [3-101. However, because 
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of the frequency of MAC strains that develop resistance 
to macrolides [6,11] and the common drug interaction 
between :macrolides, rifabutin and agents used to treat 
HIV-1 or other opportunistic infections associated with 
AIDS [li!,13], additional agents to treat disseminated 
MAC inkction are needed. 
HMR3004 (formerly RU64004) belongs to a new 
distinct class of 14-membered-ring macrolide anti- 
bacterials, the ketolides. Ketolides are characterized by 
a 3-keto function on the macrolactone ring instead 
of the L-cladnose moiety previously believed to be 
essential for the antibacterial activity of macrolides [14]. 
HMR3004 has been shown to be one of the most 
active conipounds of a series of 11,12-cyclo-substituted 
ketolides. HRM3004 has been shown to be very active 
against Streptococcus pneumoniae, Haemophilus intfluenzae, 
streptococci of group A, and Moraxella catarrhalis 
[15]. Because HMR3004 is very active against Gram- 
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positive bacteria (most of the agents active against 
MAC are also active against Gram-positive organisms) 
and also against some macrolide-resistant bacteria, we 
decided to examine the activity of HMR3004 against 
MAC strains. 
MATERIALS AND METHODS 
Antimicrobial agents 
HMR3004 (formerly RU64004) was provided by 
Roussel Uclaf (Romanville, France). Clarithromycin 
was kindly provided by Abbott Pharmaceuticals, Inc. 
(Chicago, IL, USA). The potency of the drug stock 
was confirmed by using the standard American Type 
Culture Collection quality control strains Escherichia coli 
ATCC 25922 and Staphylococcus aureus ATCC 29213. 
HMR3004 and clarithromycin were prepared for 
gavage by mssolving in a minimal amount of ethanol 
and diluting with a saturated sucrose syrup. 
For in vitro studies, both drugs were solubilized in 
dimethylsulfoxide (DMSO) and subsequently diluted 
in Hank's balanced salt solution (HBSS). Controls were 
run in parallel using the concentration of DMSO 
present in the final solution. 
Mycobacteria 
The strains of MAC used in this study (100, 101, 102, 
103, 104, 105, 107, 108, 109, 110, 111, 113, 115, 117, 
128, 500, 501, 502, 503, 504, 505, 506, 507, 508 and 
macrolide-resistant 511, 512, 513, 405-201-1, 71-163- 
1, JJLOO4-1, JWTOOS-1, TDH005-8) were isolated 
&om the blood of HIV patients (each strain was isolated 
from a different AIDS patient) with disseminated MAC 
disease, and each isolate was identified as Mycobacterium 
avium by using a commercially available DNA probe 
(Gen-Probe Inc., San Diego, CA, USA). MAC 10lR 
is a clarithromycin-resistant strain isolated in mice [16]. 
MAC strain 101 (serovar l) ,  MAC strain 109 (serovar 
4) and MAC strain 100 (serovar 8) were used for all 
macrophage assays. MAC strain 101 was used in the 
animal studies. MAC 101 is the most virulent strain 
we have tested in the beige mouse test system, and 
this strain causes reproducible levels of infection and 
mortality in beige mice [4]. MAC organisms were 
cultured in Middlebrook agar 7H10 medium (Difco 
Laboratories, Detroit, MI, USA) supplemented with 
oleic acid, albumin, dextrose, and catalase (OADC, 
Difco) for 10 days at 37OC. Only transparent colony 
types were used in the studies. For the macrophage and 
mice studies, colonies were harvested and suspended 
in HBSS to concentrations of 1 x 10' and 3 x 10' 
CFU/mL, respectively, by comparison with a McFarland 
no. 1 turbidity standard; samples were plated onto 
7H10 agar to confirm the concentration of the inoc- 
ulum. 
Beige mice were infected with 100 pL of the 
original suspension (3 x lo7 bacteria of MAC 101). 
Before infection of macrophages, the suspension was 
vortex agitated for 2 min, and passed through a 23- 
gauge needle five times to disperse clumps. Micro- 
scopic observation confirmed the dispersion of the 
inoculum. 
In vitro susceptibility testing 
MICs were determined using a radiometric broth 
macrodilution method and the TlOO method of data 
analysis [17]. The inoculum for susceptibility testing 
was prepared by picking 5-10 colonies from a 7Hl1 
agar plate into 7H9 broth and was tested directly 
or frozen at -70°C. The inoculum was adjusted to 
approximately 5 x lo4 CFU/mL by comparison with 
a McFarland no. 1 turbidity standard. Isolates that 
clumped and could not be easily dispersed were shaken 
with glass beads. Controls included the inoculum 
undiluted without drug added (no drug control), the 
inoculum dduted 1: 100 (99% control), and the inoculum 
diluted 1:lOOO (99.9% control). In addition, one vial 
was inoculated with a suspension of mycobacteria 
whch were boiled for 5 min prior to inoculation in 
order to monitor the non-growth-related release of 
carbon dioxide in the BACTEC system. The period of 
observation and endpoints were determined by daily 
monitoring of the control and test cultures, but a 
period of 7 days was sufficient for most isolates. MAC 
101 was tested against amikacin to control for overall 
test performance. 
Human macrophage studies 
The source of macrophages was the human monocyte 
cell line U937 cultured in RPMI 1640 medium (pH 
7.2) (Gibco, Chicago, IL, USA) supplemented with 5% 
fetal bovine serum (Sigma Chemical Co.) and 2 mM 
L-glutamine. Cells were grown to a density of 5 x 10' 
cells/mL and then centrifuged, washed, and resus- 
pended in supplemented RPMI 1640 medium. The 
concentration of cells was adjusted to 1 x 106 cells/ml, 
and 1 mL of the cell suspension was added to each well 
of a 24-well tissue-culture plate (Costar, Cambridge, 
MA, USA). Monolayers were treated with 0.5 mg of 
phorbol myristate acetate/mL for 24 h to stimulate 
maturation of the monocytes. The monolayers were 
monitored for the number of cells, and no ddference 
was observed in the extent of cell detachment among 
the several treatment and control groups. 
MAC 101 was cultured for 10 days in Middlebrook 
agar 7H10 medium (Difco Laboratories). On the day 
of the experiment, bacteria were harvested, washed 
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twice in HBSS, and suspended in HBSS, and a 
dispersed inoculum was prepared as described above. 
The turbidity of the suspension was adjusted to be 
equivalent to that of a McFarland no. 1 turbidity 
standard, and the suspension was diluted to a final 
concentration of approximately 5 x lo7 CFU/mL. Each 
monolayer was infected with 100 pL of the final 
suspension, and the actual number of CFUs per mL of 
the final suspension was determined by quantitative 
plate counts. Four hours after infection, the number 
of CFUs of mycobacteria per well of macrophage 
monolayer was determined by lysing the macrophages 
and performing quantitative plate counts to establish 
the initial inoculum (baseline) as previously reported 
[18]. Infected monolayers were then treated with 
HMR3004. Drug and medium were replenished 
daily for 4 days. After the treatment period (4 days), 
medium was removed and the monolayers were lysed 
as described [18]. Briefly, ice-cold sterile water 
(0.5 mL,) was added to each monolayer well, and the 
mixture was allowed to stand for 10 min at room 
temperature. Then, 0.5 mL of a second lysing solution 
(1.1 mL of Middlebrook 7H9 broth plus 0.4 mL of 
0.25% sodium dodecylsulfate (SDS) in phosphate 
buffer) was added to each well, and the mixture was 
allowed to stand for an additional 10min. The wells 
were vigorously scraped with a rubber policeman, and 
the macrophage lysates were resuspended in 0.5 mL of 
20% bovine serum in sterile water to neutralize the 
SDS. The suspension was vortex agitated for 2 min to 
ensure complete lysis of the macrophages. Finally, the 
lysate was sonicated for 5 s to disrupt clumps of bacilli. 
To control for the osmotic stability of the myco- 
bacteria, a suspension of mycobacteria alone was plated 
for quantitation before and after being subjected to the 
lysis procedure as described above, and in each instance 
there was no change in the CFUs/mL before or after 
the lysis treatment procedure. 
The final macrophage lysate suspension was serially 
diluted, and 0.1 mL was plated on 7H10 agar. The 
plates were allowed to dry a t  room temperature for 
15 min and incubated at 37OC in 5% COz for 2 weeks. 
Duplicate plates were prepared for each well, and 
the results were reported as the mean CFUs/mL of 
macrophage lysate. Each assay was performed in 
triplicate, and each experiment was repeated s i x  times. 
Animal test system 
The potential therapeutic egcacy of HMR3004 was 
determined by using the beige mouse test system as 
previously described [9,18]. This system employs 6-7- 
week-old female C57 BL/6 bg+bg+ mice aackson 
Laboratories, Bar Harbor, ME, USA). Briefly, mice 
were infected through the caudal vein with 3 x 10’ 
bacteria of MAC 101 and, after 7 days, treatment 
was initiated with HMR3004 at 50 mg/kg per day, 
100 mg/kg per day, or 200 mg/kg per day. The drug 
was administered by daily gavage for 28 days. A control 
group ofmice was infected but received sucrose syrups 
in place of the antibiotic. An additional group of mice 
was examined 7 days after infection in order to establish 
the level of infection before the initiation of therapy. 
Sixteen mice were used for each of the control and 
experim.ental groups. At the termination of therapy, the 
livers and spleens of the control and treated mice were 
aseptically removed, weighed and then homogenized in 
5 mL of 7H9 broth (Difco) with a tissue homogenizer. 
The tissue suspensions were serially diluted in 7H9 
broth and plated onto 7H11 agar plates supplemented 
with oleic acid, albumin, dextrose and catalase 
(OADC) for quantitation of viable bacteria. The 
number of mycobacteria in the blood was determined 
by collecting 0.05 mL of blood at day 7 and day 
28. The CFU per mL of blood was determined by 
inoculating a measured volume of blood into 4 mL of 
BACTIX 12 B medium (Johnston Laboratories, 
Sparks, Nv, USA) and using the TlOO method of data 
analysis as previously described [17]. 
Statistical analysis 
The dillferences between results of untreated control 
and experimental groups in macrophage experiments 
at identical time points were determined by the 
Studenit’s t-test. The statistical significance of the 
differences between the number of organisms recovered 
from the spleens, livers and blood was evaluated by 
one- or two-variable analysis of variance. Differences 
between results for experimental groups and between 
results of experimental groups and control groups were 
considered statistically significant if p values were 
<0.05. 
RESULTS 
MIC studies 
The M.IC at w h c h  50% of the isolates were inhibited 
and the MIC90 for HMR3004 was 8mg/L and 
16 mg/L, respectively. Table 1 shows the discrete 
MICs by radiometric broth macrodilution for 24 MAC 
strains (at pH 6.8, the pH of MAC within macrophage 
vacuoles [19]). For five of the strains, the MIC was also 
determined at pH 7.2. 
Cross-resistance studies with macrolides 
To determine whether clarithromycin-resistant strains 
of MAC were also resistant to HMR3004, we deter- 
mined the MICs of HMR3004 for nine clarithro- 
mycin-resistant strains (three isolates from pediatric 
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Table 1 MICs of HMR3004 against 24 MAC strains from 
AIDS patients 
~~ 
MIC (mg/L) 
MAC strains pH 6.8 pH 7.2 
100 
101 
102 
103 
104 
105 
107 
108 
109 
110 
111 
113 
116 
117 
128 
500 
501 
502 
503 
504 
505 
506 
507 
i 0 8 
8 
8 
16 
4 
8 
8 
16 
4 
4 
8 
8 
4 
4 
8 
8 
1 
16 
16 
4 
16 
16 
4 
16 
8 
- -  
MIC 50%: 8 mg/L. 
MIC 90%: 16 mg/L. 
patients, five isolates from adults, and one isolate, MAC 
101R, selected in mice treated with clarithromycin). 
All nine macrolide-resistant strains were shown to 
be cross-resistant with HMR3004 (HMR3004 MIC 
>27 mg/L). 
Human macrophage studies 
As shown in Figure 1. HMR3004 was significantly 
active against MAC 100 (p=0.009), MAC 101 
(p=0.003) and MAC 109 (p=0.002) at concentrations 
as low as 0.25 mg/L compared with untreated controls 
at the same time point. Although there was a 
statistically significant reduction in the number 
of intracellular bacteria in monolayers treated with 
HMR3004, the activity of the compound against 
the three MAC strains was clearly bacteriostatic and 
not bactericidal. This conclusion is based on the 
observation that after 4 days of treatment the number 
of bacteria in treated monolayers was lower than in 
untreated monolayers but was greater than baseline 
control. 
Animal studies 
HMR3004 was administered at a dosage of 50, 100 
and 200 mg/kg per day for 4 weeks to MAC-infected 
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Figure 1 Activity of HMR3004 against MAC 100 (a), 
MAC 101 (b) and MAC 109 (c) in the macrophage system. 
HMR3004 was inhibitory for all three strains at 
concentrations 5 0.25 mg/L. 
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Figure 2 Effect of HMR3004 on mortality of MAC-infected beige mice. Mice were infected with MAC 101, and, 7 days 
afier infection, therapy was initiated with three different doses ofHMR3004. Mice were treated daily for 28 days. 
Table 2 Effect of HMR3004 on the level of MAC 
bacteremia in beige mice 
Table 3 Effect of the treatment with HMR3004 on 
bacterial load in liver and spleen of beige mice 
Treatment No. of A log CFU/mL 
groups‘ mice of bloodb p value 
Untreated control 13 +0.17f0.33 
HMR3004 16 -0.17 f 0.36” 0.07 
(50 mdkg) 
HMR3004 16 -1.49k 0.27” 0.01 
(100 mg/kg) 
HMR3004 16 -0.75k 0.33” 0.02 
(200 mg/kg) 
~~~~ ~ 
’Mice were treated for 4 weeks. 
’Difference between CFU/mL of blood at day 0 (7 days after 
infechon) and day 28. 
beige mice. The mortahty in control mice was 37%, 
compared with 6% of mice that received 50 mg/kg per 
day, 12% of mice receiving 100 mg/kg per day, and 
6% of mice treated with 200 mg/kg per day (p<0.05 
for all comparisons with control mice) (Figure 2). In 
addition, treatment with HMR3004 resulted in sign- 
ficant reductions in the number of bacteria in the 
blood (100 and 200 mg/kg dosages) compared with 
the untreated control group (p=O.Ol and p=0.02, 
respectively) (Table 2). Treatment with HMR3004 
was also associated with significant reductions in the 
number of MAC organisms per gram of liver 
CFU/g 
Treatment No. of 
groups” mice Liver Spleen 
1-week confro1 11 2.6k0.4~10’ 7.8?1.5xlO7 
Untreated control 13 2 . 0 k 0 . 2 ~  lo8 4.1 k 0 . 7 ~  lo8 
HMR3004 
(50 mg/kg) 16 1.0+0.2x108 2 . 7 k 0 . 5 ~ 1 0 ~ ~  
HMR3004 
(100 mg/kg) 16 7 . 8 2 1 . 0 ~  1 . 3 f 0 . 2 ~  108’,‘ 
HMR3004 
(200 mg/kg) 16 4 . 8 ~ 1 . 2 ~ 1 0 ~ ” ‘ ~ ~  1 . 0 f 0 . 3 ~  108‘~c 
”Mice were treated daily for 4 weeks. 
bp< 0.05 compared with untreated control. 
‘ p <  0.05 compared with HMR3004 at 50 mg/kg per day. 
dp<0.05 compared w t h  HMR3004 at 100 mg/kg per day. 
(100 mg/kg and 200 mg/kg dosages; ~ ’ 0 . 0 4  and 
p =0.01, respectively) and spleen (all three dosages, 
p=0.02, ,D= 0.01, ~ ~ 0 . 0 1 )  compared with levels of 
infection in the same sites in the untreated control 
group (Table 3). 
DISCUSSION 
We showed that HMR3004, a ketolide, has activity 
against the: MAC strains tested in vitro at concentrations 
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5 16 mg/L, in the macrophage system and is effective 
against MAC 101 (MIC 8 mg/L) in the beige mouse. 
HMR3004 belongs to a new class of antibiotics, 
the ketolides. Ketolides contain a keto function at 
position 3 of the macrolactone ring instead of 
L-cladinose, a neutral sugar [14,15]. In addition, the 
molecule contains an 1 1-1 2 cyclic hydrazono-carba- 
mate substituted with an alkyl-aryl chain carrying 
a quinoline nucleus. The result of these structural 
changes is that ketolides are fundamentally different 
from macrolides, and this is reflected in the spectrum 
of activity and in vitro potency [14,15]. HMR3004 
exhibits strong activity against most multiresistant 
Gram-positive cocci. 
Our studies demonstrated that HMR3004 is active 
in vitro against MAC strains with MICs comparable 
to the MIC of clarithromycin [ll]. In addition, the 
activity of HMR3004 was greater at pH 7.2 than at pH 
6.8. Following ingestion by mononuclear phagocytes, 
MAC is found within a cytoplasmic vacuole that 
has been shown by several groups not to acidifj (pH 
6.8-6.9) and not to fuse with lysosomes [19]. There- 
fore, the results obtained at pH 6.8 are likely to be more 
relevant regarding the site of MAC inside macrophages. 
A recent study by Chastellier and colleagues has shown 
that clarithromycin is less active against MAC within 
macrophages than in vitro, and that the intravacuolar 
activity of clarithromycin is impaired [20]. 
Probably because HMR3004 can concentrate intra- 
cellularly, it was inhibitory against intracellular MAC 
strains at an extracellular concentration of 0.25 mg/L 
[21]. The activity of HMR3004 against MAC strains in 
macrophages was bacteriostatic, similar to the activity 
of clarithromycin against intracellular MAC in the same 
test system [22]. 
Resistance to macrolides in mycobacteria is due 
to single base mutations in the 16s rRNA [23,24] or 
mutation in the ribosome 1251. The observation that 
macrolide-resistant MAC strains showed cross-resistance 
to HMR3004 suggests that the targets for HMR3004 
and clarithromycin in MAC may be the same. None- 
theless, further studies need to be carried out to 
determine whether the frequency of resistance to 
H M R  3004 is similar to the frequency of resistance to 
clarithromycin. 
HMR3004 was effective in significantly reducing 
the number of MAC organisms in blood, liver and 
spleen at both 100 mg/kg per day and 200 mg/kg per 
day, although no dose-dependent effect was observed 
on mortality. The effect of HMR3004 in the liver and 
spleen was primarily bacteriostatic, i.e. the number of 
bacteria in liver and spleen at 7 days (beginning of the 
therapy) was lower than the number of bacteria in liver 
and spleen of mice after receiving HMR3004 for 4 
weeks. These results are consistent with the obser- 
vations made with the macrophage system. 
The results reported here suggest that the ketolide 
HMR3004 should be further evaluated as a drug with 
potential for use in treating MAC disease. However, no 
clear advantage has been seen when one compares the 
anti-MAC activity of HMR3004 and clarithromycin. 
Nonetheless, further studies are needed to determine if 
HMR3004 is effective as a prophylactic agent for MAC 
infection, as well as if the use of HMR3004 results 
in emergence of resistant strains of MAC, similar to 
what has been observed with clarithromycin both in 
experimental animal models and in humans [6,16,25]. 
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